New Paper Published in "Stem Cells" Reporting In-Vivo Migration Ability of Brainstorm...

New Paper Published in "Stem Cells" Reporting In-Vivo Migration Ability of Brainstorm Cell Therapeutics' NTF Cells

NEW YORK & PETACH TIKVAH, Israel--(Business Wire)--
BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI), a leading
developer of adult stem cell technologies and therapeutics, is pleased
to announce that the company's new therapeutic approach for treating
neurodegenerative disease was highlighted in a recent scientific paper
that was published in "Stem Cells" highlighting the company's patent
technology for treating neurodegenerative diseases. "Stem Cells" is
the most well known journal recording findings in the stem cell field.
The paper was authored by Tel Aviv University scientists.

The paper, reporting the recent work of Laboratory of
Neurosciences, FMRC, Department of Neurology, Rabin Medical Center,
Sackler Faculty of Medicine, Tel Aviv University, headed by
BrainStorm's Chief Consultants Prof. Eldad Melamed and Dr. Dani Offen,
analyzes and discusses rat NTF cells' ability to migrate in the brain
from the place of transplantation to damaged regions.

The NTF cells are generated from adult bone marrow derived stem
cells, and intended for autologous transplantation in Parkinson's
patients. The cells produce and secrete neurotrophic factors, which
are essential for the survival and outgrowth of neurons. The
production process of these cells, are Brainstorm's intellectual
property. This study shows that in a rat model of Huntington's
disease, a hereditary neurodegenerative disease, NTF cells that were
transplanted at a distance site, migrated towards the lesion at 19
days post grafting. This finding indicates the survival, integration
and migration abilities of NTF cells in the brain.

"The results of this study suggest that when our cells are
transplanted into the human brain, they may know where they are
needed, and may migrate to the damaged part of the brain, where they
will hopefully demonstrate their therapeutic capacity, and provide
trophic support for ill-functioning tissues. This recent study
provides additional support that we are on the right track," commented
Dr. Dani Offen, BrainStorm's Chief scientific advisor.

About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. is an emerging company
developing adult stem cell therapeutic products, derived from
autologous (self) bone marrow cells, for the treatment of
neurodegenerative diseases. The NurOwn(TM) patent pending technology
is based on discoveries made by the scientific team led by prominent
neurologist Professor Eldad Melamed, Head of Neurology at Rabin
Medical Center, and expert cell biologist Dr. Daniel Offen, Head of
the Neuroscience Laboratory at the Felsenstein Medical Research Center
of Tel-Aviv University. The technology allows for the differentiation
of bone marrow-derived stem cells into functional neurons and
astrocytes, as demonstrated in animal models. The Company holds rights
to develop and commercialize the technology through an exclusive,
worldwide licensing agreement with Ramot at Tel Aviv University Ltd.,
the technology transfer company of Tel-Aviv University. The Company's
initial focus is on Parkinson ALS and Spinal Cord Injury, although its
technology has promise for treating several other diseases including
MS, Huntington's disease and stroke.

Safe Harbor Statement

Statements in this announcement other than historical data and
information constitute "forward-looking statements" and involve risks
and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s
actual results to differ materially from those stated or implied by
such forward-looking statements, including BrainStorm's ability to
complete its equity financing transactions previously disclosed. The
potential risks and uncertainties include, among others, risks
associated with BrainStorm Cell Therapeutics Inc.'s limited operating
history, history of losses and expectation to incur losses for the
foreseeable future; dependence on its license to Ramot's technology;
ability, together with its licensor, to adequately protect the
NurOwn(tm) technology; dependence on key executives and on its
scientific consultants; ability to identify, negotiate and
successfully implement strategic partnering relationships; ability to
complete clinical trials successfully and to obtain required
regulatory approvals; competition with companies, some of which have
greater resources and experience in developing and obtaining
regulatory approval for treatments in BrainStorm Cell Therapeutics
Inc.'s market; the limited public trading market for BrainStorm Cell
Therapeutics Inc.'s stock which may never develop into an active
market; and other factors detailed in BrainStorm Cell Therapeutics
Inc.'s annual report on Form 10-KSB, quarterly reports on Form 10-QSB,
current reports on Form 8-K and other filings with the Securities and
Exchange Commission available at http://www.sec.gov/ or by request to
the Company. The Company does not undertake any obligation to update
forward-looking statements made by us.

BrainStorm Cell Therapeutics Inc.
Chaim Levinson, +972-545-633683
Clevinson@brainstorm-cell.com

Copyright Business Wire 2008